



**Australian Government**  

---

**Department of Health and Ageing**

**SCHEDULE OF PHARMACEUTICAL  
BENEFITS FOR DENTAL  
PRACTITIONERS**

**SUMMARY OF CHANGES**

**EFFECTIVE 1 AUGUST 2009**

# PHARMACEUTICAL BENEFITS

These changes to the Schedule of Pharmaceutical Benefits for Dental Practitioners are effective from 1 August 2009. The Schedule is updated on the first day of each month and is available on the Internet at [www.pbs.gov.au](http://www.pbs.gov.au).

## SUMMARY OF CHANGES

### ADDITIONS

#### *Additions — Items*

- 5005K **Glucose**, I.V. infusion 139 mmol (anhydrous) per 500 mL (5%), 500 mL (*BR, PK*)  
5021G **Sodium chloride**, I.V. infusion 77 mmol per 500 mL (0.9%), 500 mL (*BR, PK*)

#### *Additions — Brands*

- 5008N *APO-Amoxicillin/Clavulanic Acid 500/125, TX* — **Amoxicillin with clavulanic acid**, Tablet 500 mg-125 mg  
5009P *Curam, SZ* — **Amoxicillin with clavulanic acid**, Powder for syrup 125 mg-31.25 mg per 5 mL, 75 mL  
5011R *Curam Duo, SZ* — **Amoxicillin with clavulanic acid**, Powder for syrup 400 mg-57 mg per 5 mL, 60 mL  
3316M *APO-Paracetamol/Codeine/500/30, TX* — **Codeine phosphate with paracetamol**, Tablet 30 mg-500 mg  
5106R *BR* — **Glucose**, I.V. infusion 278 mmol (anhydrous) per L (5%), 1 L  
5164T *Momex SR 10, SI* — **Morphine sulfate**, Tablet 10 mg (controlled release)  
5165W *Momex SR 30, SI* — **Morphine sulfate**, Tablet 30 mg (controlled release)  
5166X *Momex SR 60, SI* — **Morphine sulfate**, Tablet 60 mg (controlled release)  
5167Y *Momex SR 100, SI* — **Morphine sulfate**, Tablet 100 mg (controlled release)  
5196L *APO-Paracetamol, TX* — **Paracetamol**, Tablet 500 mg  
5224Y *APO-Paracetamol, TX* — **Paracetamol**, Tablet 500 mg (**Diff. Max. Qty**)  
5212H *BR* — **Sodium chloride**, I.V. infusion 154 mmol per L (0.9%), 1 L  
5221T *APO-Temazepam, TX* — **Temazepam**, Tablet 10 mg

#### *Additions — Bioequivalence Indicators*

The bioequivalence indicator (a) has been added to the following brands:

- 5106R *BX* — **Glucose**, I.V. infusion 278 mmol (anhydrous) per L (5%), 1 L  
5212H *BX* — **Sodium chloride**, I.V. infusion 154 mmol per L (0.9%), 1 L

### DELETIONS

#### *Deletions — Brands*

- 5196L *Parmol, SI* — **Paracetamol**, Tablet 500 mg  
5224Y *Parmol, SI* — **Paracetamol**, Tablet 500 mg (**Diff. Max. Qty**)

### ALTERATIONS

#### *Alterations — Manufacturer's Code*

		<i>From</i>	<i>To</i>
3313J	<b>Ampicillin</b> , Powder for injection 500 mg ( <i>Ibimicyn</i> )	GM	TS
3314K	<b>Ampicillin</b> , Powder for injection 1 g ( <i>Ibimicyn</i> )	GM	TS
5094D	<b>Flucloxacillin</b> , Powder for injection 500 mg ( <i>Flubiclox</i> )	GM	TS
5095E	<b>Flucloxacillin</b> , Powder for injection 1 g ( <i>Flubiclox</i> )	GM	TS

### RETENTION OF BRANDS

Contrary to previous advice, the following brands will not be deleted from the Schedule of Pharmaceutical Benefits on 1 September 2009:

- 5196L *Dymadon P, PC* — **Paracetamol**, Tablet 500 mg  
5224Y *Dymadon P, PC* — **Paracetamol**, Tablet 500 mg (**Diff. Max. Qty**)